Key result
Sodium-glucose co-transporter 2 inhibitors improve survival, cardiovascular mortality, and hospitalization in HFrEF patients receiving standard neurohumoral modulation therapies.
Why the study?
Do sodium-glucose co-transporter 2 inhibitors improve mortality and hospitalization in patients with HFrEF receiving standard therapy?
Do sodium-glucose co-transporter 2 inhibitors improve mortality and hospitalization in patients with HFrEF receiving standard therapy?
SGLT2 inhibitors provide significant mortality and morbidity benefits in HFrEF patients already receiving optimal medical therapy including ARNIs.
Current clinical guidelines for heart failure (HF) contain a brand new therapeutic strategy for HF with reduced ejection fraction (HFrEF), which is based on neurohumoral modulation through the use of angiotensin receptor neprilysin inhibitors. There is a large body of evidence for the fact that sodium-glucose co-transporter 2 inhibitors may significantly improve all-cause mortality, cardiovascular mortality and hospitalization for HF in patients with HFrEF who received renin-angiotensin system blockers including angiotensin receptor neprilysin inhibitors, β-blockers and mineralocorticoid receptor antagonists. The review discusses that sodium-glucose co-transporter 2 inhibitors have a wide spectrum of favorable molecular effects and contribute to tissue protection, improving survival in HFrEF patients.
No takes yet. Share an insight, caveat, or question.
Berezin et al. (2021) conducted a review in Heart failure with reduced ejection fraction (HFrEF). Sodium-glucose co-transporter 2 inhibitors was evaluated. Sodium-glucose co-transporter 2 inhibitors improve survival, cardiovascular mortality, and hospitalization in HFrEF patients receiving standard neurohumoral modulation therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: